Atropos Health, the leader in providing physicians with research-grade real-world evidence at the point of care, has announced the completion of a $14M Series A funding round. The company will use the funds to expand its commercial team, further build on recent market traction, and continue to develop its oncology product. Breyer Capital, a global venture capital investor, led the round with participation from Emerson Collective, a multi-stage venture team focused on accelerating companies positively impacting the world. Other participating investors include Boston Millennia Partners.

Atropos Health is the developer of the first physician consultation service powered by research-grade real-world data. Using millions of anonymized patient records, Atropos helps providers answer clinical questions that have fallen through the cracks of the evidence-based literature. By leveraging insights from free-text notes and other non-standard data entries that often go overlooked, Atropos empowers more robust research and effective care delivery.